Symbols / AMIX
AMIX Chart
About
Autonomix Medical, Inc., a development stage medical device company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. The company's technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. It develops technology for patients with pancreatic cancer and addresses indications for chronic pain management, hypertension, cardiovascular, and other nerve-related disorders. Autonomix Medical, Inc. was incorporated in 2014 and is headquartered in The Woodlands, Texas.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Medical Devices | Market Cap | 4.26M |
| Enterprise Value | -5.68M | Income | -17.24M | Sales | — |
| Book/sh | 0.75 | Cash/sh | 0.87 | Dividend Yield | — |
| Payout | 0.00% | Employees | 8 | IPO | — |
| P/E | — | Forward P/E | -0.05 | PEG | — |
| P/S | — | P/B | 0.50 | P/C | — |
| EV/EBITDA | 0.32 | EV/Sales | — | Quick Ratio | 6.02 |
| Current Ratio | 6.18 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -4.51 | EPS next Y | -7.40 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-02-11 17:00 | ROA | -98.98% |
| ROE | -188.75% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 11.41M |
| Shs Float | 11.06M | Short Float | 8.56% | Short Ratio | 0.07 |
| Short Interest | — | 52W High | 3.04 | 52W Low | 0.34 |
| Beta | -2.56 | Avg Volume | 3.39M | Volume | 58.24K |
| Target Price | $2.00 | Recom | Strong_buy | Prev Close | $0.36 |
| Price | $0.37 | Change | 4.27% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$2.00
Mean price target
2. Current target
$0.37
Latest analyst target
3. DCF / Fair value
$-9.36
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.37
Low
$2.00
High
$2.00
Mean
$2.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-17 | main | Maxim Group | Buy → Buy | $2 |
| 2025-04-29 | init | Maxim Group | — → Buy | $5 |
| 2024-09-03 | init | Ladenburg Thalmann | — → Buy | $1 |
- Autonomix CEO on validating nerve-targeting tech through peer review - Stock Titan Wed, 25 Feb 2026 13
- Autonomix Medical stock soars after cancer pain therapy shows quality-of-life gains - Investing.com Mon, 17 Nov 2025 08
- New data tests minimally invasive nerve treatment for pancreatic cancer pain - Stock Titan hu, 19 Feb 2026 13
- Autonomix Medical, Inc. (AMIX) Upgraded to Strong Buy: Here's Why - Yahoo Finance hu, 31 Jul 2025 07
- AMIX Stock Price and Chart — NASDAQ:AMIX - TradingView ue, 29 Jul 2025 07
- Autonomix Medical (AMIX) Price Target Slashed by Maxim Group | A - GuruFocus ue, 17 Feb 2026 20
- AMIX Stock May Climb Following Key U.S. Patent for Nerve-Sensing Tech - Nasdaq hu, 22 May 2025 07
- AMIX Stocks Surge: What’s Fueling the Momentum? - timothysykes.com Mon, 17 Nov 2025 08
- 12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga ue, 03 Feb 2026 08
- Will Autonomix Medical Inc. Stock Soar? - StocksToTrade Mon, 17 Nov 2025 08
- Autonomix Medical Receives Nasdaq Minimum Bid Price Notice - TipRanks Fri, 16 Jan 2026 08
- Maxim Group Maintains Autonomix Medical(AMIX.US) With Buy Rating, Maintains Target Price $2 - 富途牛牛 ue, 17 Feb 2026 14
- New patent backs tech that targets heart nerves across tough diseases - Stock Titan ue, 30 Dec 2025 08
- Autonomix Medical, Inc. Announces Pricing of $5.0 Million Private Placement Priced At The Market Under Nasdaq Rules - Yahoo Finance ue, 18 Nov 2025 08
- Maxim Group Initiates Coverage of Autonomix Medical (AMIX) with Buy Recommendation - Nasdaq ue, 29 Apr 2025 07
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2025-03-31 | 2024-03-31 | 2023-03-31 |
|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -11.05M | -7.27M | -1.99M |
| TotalUnusualItems | -8.00M | ||
| TotalUnusualItemsExcludingGoodwill | -8.00M | ||
| NetIncomeFromContinuingOperationNetMinorityInterest | -11.41M | -15.43M | -1.99M |
| ReconciledDepreciation | 183.00K | 81.00K | 0.00 |
| EBITDA | -11.05M | -15.27M | -1.99M |
| EBIT | -11.23M | -15.35M | -1.99M |
| NetInterestIncome | 178.00K | 48.00K | 0.00 |
| InterestExpense | 176.00K | 79.00K | 0.00 |
| InterestIncome | 354.00K | 127.00K | 0.00 |
| NormalizedIncome | -11.41M | -7.43M | -1.99M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -11.41M | -15.43M | -1.99M |
| TotalExpenses | 11.59M | 7.47M | 1.99M |
| TotalOperatingIncomeAsReported | -11.59M | -12.03M | -1.99M |
| DilutedAverageShares | 1.77M | 1.04M | 1.06M |
| BasicAverageShares | 1.77M | 1.04M | 1.06M |
| DilutedEPS | -6.46 | -14.82 | -1.88 |
| BasicEPS | -6.46 | -14.82 | -1.88 |
| DilutedNIAvailtoComStockholders | -11.41M | -15.43M | -1.99M |
| NetIncomeCommonStockholders | -11.41M | -15.43M | -1.99M |
| NetIncome | -11.41M | -15.43M | -1.99M |
| NetIncomeIncludingNoncontrollingInterests | -11.41M | -15.43M | -1.99M |
| NetIncomeContinuousOperations | -11.41M | -15.43M | -1.99M |
| TaxProvision | 0.00 | 0.00 | 0.00 |
| PretaxIncome | -11.41M | -15.43M | -1.99M |
| OtherIncomeExpense | -8.00M | ||
| GainOnSaleOfSecurity | -8.00M | ||
| NetNonOperatingInterestIncomeExpense | 178.00K | 48.00K | 0.00 |
| InterestExpenseNonOperating | 176.00K | 79.00K | 0.00 |
| InterestIncomeNonOperating | 354.00K | 127.00K | 0.00 |
| OperatingIncome | -11.59M | -7.47M | -1.99M |
| OperatingExpense | 11.59M | 7.47M | 1.99M |
| ResearchAndDevelopment | 4.72M | 2.23M | 745.00K |
| SellingGeneralAndAdministration | 6.86M | 5.25M | 1.25M |
| GeneralAndAdministrativeExpense | 6.86M | 5.25M | 1.25M |
| OtherGandA | 6.86M | 5.25M | 1.25M |
| TotalRevenue | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 |
| Line Item | 2025-03-31 | 2024-03-31 | 2023-03-31 |
|---|---|---|---|
| OrdinarySharesNumber | 2.50M | 942.30K | 1.06M |
| ShareIssued | 2.50M | 942.30K | 1.06M |
| TotalDebt | 1.00M | ||
| TangibleBookValue | 8.10M | 7.63M | 644.00K |
| InvestedCapital | 8.10M | 8.63M | 644.00K |
| WorkingCapital | 7.90M | 8.61M | 644.00K |
| NetTangibleAssets | 8.10M | 7.63M | 644.00K |
| CommonStockEquity | 8.10M | 7.63M | 644.00K |
| TotalCapitalization | 8.10M | 8.63M | 644.00K |
| TotalEquityGrossMinorityInterest | 8.10M | 7.63M | 644.00K |
| StockholdersEquity | 8.10M | 7.63M | 644.00K |
| RetainedEarnings | -50.38M | -38.97M | -23.54M |
| AdditionalPaidInCapital | 58.48M | 46.60M | 24.18M |
| CapitalStock | 2.00K | 1.00K | 12.00K |
| CommonStock | 2.00K | 1.00K | 12.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 1.71M | 1.78M | 221.00K |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 0.00 | 1.00M | 0.00 |
| LongTermDebtAndCapitalLeaseObligation | 1.00M | ||
| LongTermDebt | 1.00M | ||
| CurrentLiabilities | 1.71M | 777.00K | 221.00K |
| PayablesAndAccruedExpenses | 1.71M | 777.00K | 221.00K |
| CurrentAccruedExpenses | 1.03M | 285.00K | 48.00K |
| Payables | 676.00K | 492.00K | 173.00K |
| AccountsPayable | 676.00K | 492.00K | 173.00K |
| TotalAssets | 9.81M | 9.41M | 865.00K |
| TotalNonCurrentAssets | 197.00K | 16.00K | 0.00 |
| NonCurrentDeferredAssets | 176.00K | 0.00 | |
| NetPPE | 21.00K | 16.00K | 0.00 |
| CurrentAssets | 9.61M | 9.39M | 865.00K |
| OtherCurrentAssets | 473.00K | 783.00K | |
| CashCashEquivalentsAndShortTermInvestments | 9.14M | 8.61M | 865.00K |
| CashAndCashEquivalents | 9.14M | 8.61M | 865.00K |
| CashFinancial | 8.61M | 865.00K |
| Line Item | 2025-03-31 | 2024-03-31 | 2023-03-31 |
|---|---|---|---|
| FreeCashFlow | -8.27M | -6.67M | -1.85M |
| IssuanceOfDebt | 0.00 | 2.00M | 0.00 |
| IssuanceOfCapitalStock | 10.03M | 13.71M | 675.00K |
| CapitalExpenditure | -14.00K | -19.00K | |
| EndCashPosition | 9.14M | 8.61M | 865.00K |
| BeginningCashPosition | 8.61M | 865.00K | 2.04M |
| ChangesInCash | 528.00K | 7.74M | -1.18M |
| FinancingCashFlow | 8.80M | 14.41M | 675.00K |
| CashFlowFromContinuingFinancingActivities | 8.80M | 14.41M | 675.00K |
| NetOtherFinancingCharges | -1.23M | -1.30M | |
| ProceedsFromStockOptionExercised | 1.00K | 0.00 | |
| NetCommonStockIssuance | 10.03M | 13.71M | 675.00K |
| CommonStockIssuance | 10.03M | 13.71M | 675.00K |
| NetIssuancePaymentsOfDebt | 0.00 | 2.00M | 0.00 |
| NetLongTermDebtIssuance | 0.00 | 2.00M | 0.00 |
| LongTermDebtIssuance | 0.00 | 2.00M | 0.00 |
| InvestingCashFlow | -14.00K | -19.00K | 0.00 |
| CashFlowFromContinuingInvestingActivities | -14.00K | -19.00K | 0.00 |
| NetPPEPurchaseAndSale | -14.00K | -19.00K | 0.00 |
| PurchaseOfPPE | -14.00K | -19.00K | 0.00 |
| OperatingCashFlow | -8.26M | -6.65M | -1.85M |
| CashFlowFromContinuingOperatingActivities | -8.26M | -6.65M | -1.85M |
| ChangeInWorkingCapital | 1.24M | 79.00K | 136.00K |
| ChangeInOtherCurrentAssets | 310.00K | -478.00K | 9.00K |
| ChangeInPayablesAndAccruedExpense | 930.00K | 557.00K | 127.00K |
| ChangeInAccruedExpense | 746.00K | 237.00K | 46.00K |
| ChangeInPayable | 184.00K | 320.00K | 81.00K |
| ChangeInAccountPayable | 184.00K | 320.00K | 81.00K |
| OtherNonCashItems | 101.00K | ||
| StockBasedCompensation | 1.63M | 618.00K | 0.00 |
| DepreciationAmortizationDepletion | 183.00K | 81.00K | 0.00 |
| DepreciationAndAmortization | 183.00K | 81.00K | 0.00 |
| OperatingGainsLosses | 8.00M | ||
| GainLossOnInvestmentSecurities | 8.00M | ||
| NetIncomeFromContinuingOperations | -11.41M | -15.43M | -1.99M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for AMIX
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|